Since 2022 the team of the project "Knowledge stops Dementia" started to refer on a regular base to current contributions from the world wide web which have a close relation to our core topic, the early detection of individual risk factors and thus the lifestyle-oriented and self-responsible prevention and treatment of dementia-related diseases. The opinions expressed in the following articles should serve as a stimulus for critical discussion. They do not necessarily correspond to the positions we hold, but in all cases, they enrich the basis for discussion. Occasionally, we also refer to current freely available studies at the end – please make up your own mind!
interesting therapy option, once Alzheimer's disease is the leading cause of dementia in individuals over 65 and has a major negative impact on the lives of patients, relatives and caregivers. Furthermore, it generates a large economic and financial burden for both the patient's family and healthcare systems.
Spermidine, also known chemically as N-(3-aminopropyl) butane-1,4-diamine, is one of the naturally occurring polyamines. It occurs as a natural substance in amino acid metabolism of all living organisms and in all cells, and therefore also in a variety of plant and animal foods. Particularly rich food sources are wheat germ, but hard cheese, dried soybeans and some other foods also provide good amounts of spermidine. Recently, it was shown in mice that spermidine from food actually reaches the brain, thus crossing the blood-brain barrier.
Can cataract surgery lower the risk of dementia? – a new study shows how good vision in elderly can protect cognition.
The primary function of the nervous system is to adapt the living being to the environment. In order to accomplish [...]
With the beginning of the New Year, the team of the project "Knowledge stopps Dementia" would like to refer on a regular base to current contributions from the world wide web which have a close relation to our core topic, the lifestyle-oriented and self-responsible prevention and treatment of dementia-related diseases. The opinions expressed in the following articles should serve as a stimulus for critical discussion. They do not necessarily correspond to the positions we hold, but in all cases, they enrich the basis for discussion. Occasionally, we also refer to current freely available studies at the end - make up your own mind!
Recent study shows: the MIND diet protects against cognitive decline, even independently of the pathological changes in the Alzheimer’s brain
An intriguing question for Alzheimer's researchers is the fact that some patients manage to maintain good cognitive function despite severe brain lesions (anatomical anomaly in parts of the brain). Thus, there seems to be no correlation between the deposition of amyloid plaques and cognitive changes such as memory loss, planning difficulties, behavioral disturbances, and others.
Recently, we reported that insulin resistance is an important cause of Alzheimer’s disease. The disturbance of glucose metabolism can cause [...]
During my medical residency in neurology at the Hospital of Federal Fluminense University (UFF) in Rio de Janeiro/Brazil we often faced the following question: some medications commonly prescribed in routine neurology practice (for patients with Parkinson's syndrome, depression or urinary alterations) inhibited the neurotransmitter acetylcholine, important for the formation and maintenance of memory. Since one of the proposals for the pharmacological treatment of Alzheimer's disease is precisely to increase the concentration of acetylcholine in the brain, the use of drugs that inhibit this neurotransmitter seemed contradictory and threatening to us.
With the project "Knowledge stops Dementia", the German Foundation for Health Information and Prevention (Deutsche Stiftung für Gesundheitsinformation und Prävention DSGiP), together with the Academy for Human Medicine (Akademie für menschliche Medizin), presents a broad spectrum of lifestyle-oriented measures for the prevention and therapy of Alzheimer's disease. In addition to Alzheimer's dementia, however, other neurodegenerative diseases such as multiple sclerosis and Parkinson's disease also pose a major challenge for those affected, their relatives and, ultimately, the healthcare system, since the prospect of a cure through pharmaceutical approaches is still a long way in the future. But the good news is, individualized lifestyle concepts seem to be effective also in these diseases.
Positive news from clinical Alzheimer's research is rare. In hardly any other indication do pharmaceutical companies have to accept as many setbacks as here. To date, pharmacological approaches to treating Alzheimer's have been almost uniformly unsuccessful, with more than 400 failed clinical trials. Since 2002, there has been no new approval in the field of neurodegenerative diseases. That changed on June 7, 2021, when the drug Aducanumab, from U.S. biotech Biogen (and its Japanese research partner Eisai), was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease. The drug, which is administered intravenously to patients, will be available in the U.S. under the trade mark Aduhelm. Aduhelm works on the basis of passive immunization. It is a monoclonal antibody that targets amyloid-ß, a protein characteristic of Alzheimer's disease. These amyloid-ß proteins make up the deposits in the brain, known as plaques, which are associated with the destruction of neurones. Aduhelm's mechanism of action is based on promoting the breakdown of β-amyloid, thereby reducing the harmful plaques.